TL;DR: Aetna, a CVS Health company, modified CPB 0783 covering in vivo analysis of gastrointestinal and urothelial lesions, effective December 12, 2025. CPT codes 43206, 43252, and +0397T are explicitly not covered for the indications listed in this policy. Here's what billing teams need to do.
This update to the Aetna in vivo GI and urothelial lesion coverage policy doubles down on the payer's long-standing position: these advanced optical and endomicroscopy technologies are experimental. If your GI, pulmonology, urology, or surgical practice bills any of these codes for Aetna members, this modification is a claim denial waiting to happen. The policy covers CPB 0783 in the Aetna system and applies to a wide range of endoscopic and optical biopsy approaches—none of them covered.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions |
| Policy Code | CPB 0783 |
| Change Type | Modified |
| Effective Date | December 12, 2025 |
| Impact Level | High |
| Specialties Affected | Gastroenterology, Urology, Pulmonology, General Surgery, Thoracic Surgery, Head & Neck Surgery, Oncology |
| Key Action | Flag CPT 43206, 43252, and +0397T in your charge capture as non-covered for Aetna members before billing any endomicroscopy procedure. |
Aetna In Vivo GI and Urothelial Lesion Coverage Criteria and Medical Necessity Requirements 2025
The short version: Aetna does not cover these procedures. There are no medical necessity criteria that unlock reimbursement for confocal laser endomicroscopy, optical biopsy systems, or narrow-band imaging when billed to Aetna under CPB 0783.
This coverage policy draws a hard line. The payer classifies the entire category of in vivo optical analysis of GI and urothelial lesions as experimental, investigational, or unproven. That classification means no amount of clinical documentation will change the outcome at adjudication. Aetna's position is that effectiveness has not been established—full stop.
Prior authorization is not the issue here. These procedures aren't denied because they lack prior auth. They're denied because Aetna considers them experimental. Sending a prior authorization request for CPT 43206 or 43252 won't get you a green light. It will just slow down the denial.
The practical question for your billing team is whether you're billing these codes at all for Aetna members—and whether patients have been informed of the non-coverage before the procedure. That's where your financial exposure sits.
Aetna In Vivo Endomicroscopy Exclusions and Non-Covered Indications
This policy is almost entirely an exclusion list. There are no covered indications for the core technologies addressed in CPB 0783.
Aetna classifies all of the following as experimental or unproven:
In-vivo colorectal polyp analysis, including chromoendoscopy, confocal laser endomicroscopy (CLE), endocytoscopy, narrow-band imaging, multi-band imaging, fiberoptic analysis, the EVIS EXERA 160A System, the Optical Biopsy System, the Pentax Confocal Laser System, and the WavSTAT™ Optical Biopsy System.
Elastic-scattering spectroscopy for colonic polyp evaluation.
ERCP with optical endomicroscopy (CPT +0397T) for biliary lesion evaluation, including strictures.
Confocal laser endomicroscopy (CLE)—including Cellvizio probe-based CLE—for 29 named indications. This list is long and worth reading carefully. It includes conditions that clinicians consider strong use cases for CLE. Aetna disagrees.
The 29 non-covered CLE indications include:
| # | Excluded Procedure |
|---|---|
| 1 | Barrett's esophagus low-grade dysplasia confirmation and surveillance |
| 2 | Colorectal polyp differentiation during routine colonoscopy |
| 3 | Diagnosis of bladder cancer (histologic grading included) |
| 4 | Diagnosis of early-stage gastric or ovarian cancer |
| 5 | Staging and diagnosis of lung cancer |
| 6 | Evaluation of pancreatic cysts |
| 7 | Diagnosis of indeterminate biliary strictures and pancreatic lesions |
| 8 | Diagnosis of prostate cancer |
| 9 | Management of upper tract urothelial carcinoma |
| 10 | Inflammatory bowel disease (Crohn's disease and ulcerative colitis) diagnosis, disease course prediction, and therapeutic response monitoring |
| 11 | Assessment of surgical margins during laryngectomy |
| 12 | Intraoperative glioblastoma diagnosis and CNS tumor resection |
| 13 | Diagnosis of liver cancer |
| 14 | Diagnosis of functional dyspepsia (leaky gut disorder) |
| 15 | Acute cellular rejection in lung transplant recipients |
| 16 | Hirschsprung's disease intraoperative use |
The policy explicitly notes the list is not all-inclusive. If you're wondering whether a CLE indication not on this list might be covered—don't assume it is. The burden is on you to confirm.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| In-vivo colorectal polyp analysis (all methods) | Not Covered / Experimental | 45378, G0105, G0121 | Includes chromoendoscopy, NBI, CLE, endocytoscopy, WavSTAT™, EVIS EXERA 160A |
| Elastic-scattering spectroscopy for colonic polyps | Not Covered / Experimental | 45378 | No covered indication exists |
| ERCP with optical endomicroscopy for biliary lesions/strictures | Not Covered / Experimental | +0397T | Add-on code; Aetna considers experimental |
| Esophagoscopy with optical endomicroscopy (CLE) | Not Covered / Experimental | 43206 | All indications including Barrett's surveillance |
| EGD with optical endomicroscopy (CLE) | Not Covered / Experimental | 43252 | All indications including early gastric cancer diagnosis |
| CLE for Barrett's esophagus surveillance | Not Covered / Experimental | 43206, 43252 | Including low-grade dysplasia confirmation |
| CLE for bladder cancer diagnosis/grading | Not Covered / Experimental | — | Urology practices: flag this |
| CLE for lung cancer staging/diagnosis | Not Covered / Experimental | — | Pulmonology and thoracic surgery affected |
| CLE for pancreatic cysts | Not Covered / Experimental | +0397T | Often billed alongside ERCP |
| CLE for colorectal polyp differentiation | Not Covered / Experimental | 45378, G0105, G0121 | Routine colonoscopy context |
| CLE for IBD (Crohn's, UC) | Not Covered / Experimental | — | Diagnosis, monitoring, and therapeutic response all excluded |
| CLE for prostate cancer diagnosis | Not Covered / Experimental | — | Urology: no covered pathway |
| CLE for upper tract urothelial carcinoma | Not Covered / Experimental | — | Management context also excluded |
| CLE for glioblastoma/CNS tumor intraoperative use | Not Covered / Experimental | — | Neurosurgery: no coverage |
| CLE for laryngeal/pharyngeal SCC diagnosis | Not Covered / Experimental | — | Head and neck surgery affected |
| CLE for lung transplant rejection | Not Covered / Experimental | — | Pulmonology: excluded |
| CLE for Hirschsprung's disease (intraoperative) | Not Covered / Experimental | — | Pediatric surgery affected |
| CLE for liver cancer diagnosis | Not Covered / Experimental | — | Hepatology and GI oncology affected |
| Colorectal cancer screening colonoscopy (standard) | Other/Related | G0105, G0121 | Not an exclusion—listed as related codes; standard screening rules apply separately |
Aetna In Vivo Endomicroscopy Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your charge master for CPT 43206, 43252, and +0397T before December 12, 2025. Flag these codes in your system as non-covered for Aetna commercial plans. Any claims that drop after the effective date with these codes for Aetna members will deny. Catch them before they go out. |
| 2 | Review your advance beneficiary and financial liability workflows. Because these procedures are experimental under Aetna's coverage policy, patients must be notified before the procedure that Aetna will not pay. Your ABN or equivalent financial liability waiver needs to be in place and signed. Without it, you may not be able to collect from the patient either. |
| 3 | Check all pending claims for these CPT codes billed to Aetna. If you have claims in flight for CPT 43206, 43252, or +0397T with Aetna members, pull them now. Reimbursement is not coming. Decide whether to appeal on clinical grounds or write them off. An appeal arguing clinical effectiveness against an "experimental" designation has a low success rate, but if you have strong documentation, it may be worth the attempt. |
| 4 | Brief your endoscopy and surgical scheduling teams on the 29 excluded CLE indications. The breadth of this list is the real exposure. CLE for Barrett's surveillance, IBD monitoring, pancreatic cyst evaluation, and bladder cancer diagnosis are all common use cases. If your providers are recommending these procedures and your billers are coding them, you need alignment before the procedures are scheduled—not after. |
| 5 | Do not use G0105 or G0121 as a workaround for optical endomicroscopy add-ons. These HCPCS codes are listed as related to CPB 0783 in the context of colonoscopy. They describe standard colorectal cancer screening colonoscopy for high-risk and average-risk patients. Using them to support a claim that includes non-covered optical endomicroscopy does not change the experimental status of the add-on technology. |
| 6 | If your practice uses Cellvizio (probe-based CLE) specifically, this policy calls it out by name. The policy names Cellvizio probe-based CLE as experimental under both the colorectal polyp section and the broader CLE section. There is no Aetna-covered indication for this device under CPB 0783. If your facility has this equipment and bills Aetna patients, talk to your compliance officer about your current consent and billing practices. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for In Vivo GI and Urothelial Lesion Analysis Under CPB 0783
Not Covered / Experimental CPT Codes
| Code | Type | Description | Status |
|---|---|---|---|
| +0397T | CPT (Add-on) | Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (list separately) | Not covered for indications listed in CPB 0783 |
| 43206 | CPT | Esophagoscopy, flexible, transoral; with optical endomicroscopy (confocal laser endomicroscopy) | Not covered for indications listed in CPB 0783 |
| 43252 | CPT | Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy (confocal laser endomicroscopy) | Not covered for indications listed in CPB 0783 |
Key ICD-10-CM Diagnosis Codes Referenced in CPB 0783
The policy references 196 ICD-10-CM codes. The primary diagnosis groupings are listed below. These represent the conditions for which the non-covered procedures are typically attempted—not diagnoses that unlock coverage.
| Code / Range | Description |
|---|---|
| B65.0 | Schistosomiasis due to Schistosoma haematobium (urinary schistosomiasis) |
| C15.3–C26.9 | Malignant neoplasms of digestive organs (including early-stage gastric cancer) |
| C34.0–C34.9x | Malignant neoplasm of bronchus and lung (all subsites and laterality variants) |
The full ICD-10-CM list spans 196 codes covering lung cancers, GI malignancies, urologic cancers, inflammatory bowel disease, Barrett's esophagus, biliary strictures, pancreatic lesions, bladder cancer, and more. The presence of a diagnosis code on this list does not create a covered pathway. It identifies diagnoses associated with these non-covered procedures.
Get the Full Picture for CPT 43206
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.